Notice of Results

RNS Number : 1770U

Oxford BioDynamics PLC

13 January 2017

 

13 January 2017

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Notice of Results for the year ended 30 September 2016

Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, expects to announce its full year results for the year ended 30 September 2016 on Tuesday 31 January 2017.

-ENDS-

For further details contact:

Oxford BioDynamics Plc                                                                               [phone]

Christian Hoyer Millar, CEO

Katie Long, CFO

FTI Consulting                                                                                                   [phone]

Financial Public Relations Advisor                                                          

Julia Phillips

Brett Pollard

Natalie Garland-Collins

Matthew Moss

Stifel Nicolaus Europe Limited                                                                  [phone]

Nominated Advisor and Broker                                                                

David Arch

Jonathan Senior

Peter Lees

Ben Maddison

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

NORQXLFFDFFLBBB